Topic: Pay for delay

Judge blocks class certification against Takeda, Teva and others

A Pennsylvania federal judge has refused to certify a class of wholesale purchasers of a gout treatment medicine, finding that the claim against several major drugmakers is based on faulty expert testimony that does not hold up to rigorous analysis.

28 November 2022

Celgene, Bristol-Myers monopolised cancer drug, pharmacies say

Celgene, Bristol-Myers Squibb and two generic drugmakers engaged in a years-long conspiracy to hinder generic competition for a rare cancer medication, Walgreens and Kroger Pharmacies have alleged.

07 November 2022

Judge certifies eight classes in HIV treatment MDL

A California federal judge has certified eight out of nine proposed classes of purchasers in the HIV antitrust litigation, rebuffing drugmakers’ claims that the plaintiffs “lack typicality and adequacy” to recover damages on a classwide basis.

04 November 2022

Tickets available for GCR Live: Antitrust in Pharmaceuticals

GCR Live: Antitrust in Pharmaceuticals is returning to New York in December, with panels discussing killer acquisitions, the diverging enforcement of pay-for-delay deals and the Inflation Reduction Act.

21 October 2022

Zetia claims win magistrate blessing

Glenmark Pharmaceuticals and Merck should have to face pay-for-delay claims over the cholesterol-lowering drug Zetia at trial, a federal magistrate judge has said.

07 September 2022

Oral hearings not essential for fair appeals, CAT president says

The UK’s Competition Appeal Tribunal can oversee a fair appeal process without holding a hearing, its president has said while rejecting drugmakers' claims that oral submissions are a fundamental part of their appeals against excessive pricing penalties.

25 July 2022

All Servier agreements were by-object restrictions, AG Kokott says

The European Court of Justice should set aside a General Court decision that found agreements between Servier and generics drugmaker Krka did not constitute by-object or by-effect restrictions of competition, EU advocate general Juliane Kokott has said.

14 July 2022

Delaware court dismisses Accord claims in Seroquel antitrust litigation

Plaintiffs have failed to allege that AstraZeneca’s purported pay-for-delay agreement with Accord Healthcare harmed competition in the market for psychiatric medication Seroquel XR, a federal court has ruled.

07 July 2022

Second Circuit: Southern District of New York

Featured in US Courts Annual Review - Edition 3

In 2021, the United States Court of Appeals for the Second Circuit made key antitrust decisions in appeals from the United States District Court for the Southern District of New York.

24 June 2022

CMA fines pharma companies for restricting drug supplies

The UK’s antitrust watchdog has fined four pharmaceutical companies and a private equity group more than £35 million for agreeing to limit the supply of an anti-nausea tablet to the National Health Service, causing prices to rise by 700%.

03 February 2022

Unlock unlimited access to all Global Competition Review content